Dr Lee Dong-ki, founder and CEO
OliX Pharmaceuticals develops ribonucleotide technologies for untreatable diseases
- With key leadership in the US subsidiary comprising Asians, OliX hopes to have a strong future relationship with therapeutic companies in the Asian territory
Supported by:
Discovery Reports
Follow your favourite topic and get notified
Dr Lee Dong-ki, founder and CEO